Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Common Equity (2019 - 2026)

Opus Genetics has reported Common Equity over the past 13 years, most recently at -$45.8 million for Q1 2026.

  • Quarterly Common Equity fell 1003.53% to -$45.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$45.8 million through Mar 2026, down 1003.53% year-over-year, with the annual reading at $15.3 million for FY2025, 128.26% up from the prior year.
  • Common Equity was -$45.8 million for Q1 2026 at Opus Genetics, down from $15.3 million in the prior quarter.
  • Over five years, Common Equity peaked at $50.3 million in Q3 2023 and troughed at -$45.8 million in Q1 2026.
  • The 5-year median for Common Equity is $17.5 million (2025), against an average of $23.2 million.
  • Year-over-year, Common Equity surged 323.36% in 2023 and then plummeted 1003.53% in 2026.
  • A 5-year view of Common Equity shows it stood at $46.2 million in 2022, then increased by 7.93% to $49.9 million in 2023, then tumbled by 86.53% to $6.7 million in 2024, then soared by 128.26% to $15.3 million in 2025, then plummeted by 398.64% to -$45.8 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Common Equity are -$45.8 million (Q1 2026), $15.3 million (Q4 2025), and $6.0 million (Q3 2025).